News

The Mosaic Company has invested £2.5 million in Oxford spinout SugaROx to support the commercialisation of a precision biostimulant based on trehalose-6-phosphate, aiming to improve crop yield and nutrient use efficiency. SugaROx’s patented delivery system and single, precisely manufactured active ingredient address the longstanding issue of inconsistent field performance in biologicals, with trials showing yield improvements of up to 15% in key crops. The company’s approach focuses on building strong agronomic evidence through independent, multi-season trials to ensure farmer confidence and regulatory readiness ahead of a targeted UK launch in 2027-2028. This investment aligns with Mosaic’s strategy to expand its Biosciences platform and develop integrated solutions that optimise plant physiology and resource use.

The Mosaic Company is reducing phosphate production and capital spending due to soaring input costs and geopolitical disruptions, despite strong demand and improved production performance at key facilities. The company is shifting focus toward its rapidly growing Biosciences platform, positioning biological solutions as a future growth pillar while taking steps to preserve cash, including asset sales and workforce reductions. Potash operations remain stable, but Brazil’s market is challenging, and Mosaic’s strategy aligns with industry-wide efforts to manage margin pressure. Management remains optimistic about long-term recovery, emphasizing that fertilizer market dynamics are currently driven more by input supply and costs than by demand.